Analyst firms · H.C. Wainwright · CYTK
H.C. Wainwright CYTK price target and rating history
Cytokinetics Incorporated (CYTK) · Health Care
H.C. Wainwright rates Cytokinetics Incorporated (CYTK) Buy with a $69 price target, as of its latest action on Dec 21, 2021. It has published 4 rating actions on CYTK since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a CYTK price target in the last 12 months, the median target is $95.
- Current rating
- Buy
- Price target
- $69
- Median target, all firms
- $95
- Actions on CYTK
- 4
H.C. Wainwright price target on CYTK
Every H.C. Wainwright rating on CYTK
- Dec 21, 2021
- Nov 4, 2021
- Aug 6, 2021
- Jul 19, 2021
How other firms rate CYTK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $115 | Jun 29, 2026 |
| Citigroup | Buy | $99 | May 19, 2026 |
| Wells Fargo | Overweight | $95 | Apr 10, 2026 |
| Barclays | Overweight | $87 | Jan 28, 2026 |
| Goldman Sachs | Buy | $95 | Dec 18, 2025 |
Questions about H.C. Wainwright and CYTK
- What is H.C. Wainwright's price target for CYTK?
- H.C. Wainwright's latest stated price target for Cytokinetics Incorporated (CYTK) is $69, from its action on Dec 21, 2021.
- What is H.C. Wainwright's rating on CYTK?
- H.C. Wainwright rates CYTK Buy, a bullish rating, as of Dec 21, 2021.
- When did H.C. Wainwright last change its view on CYTK?
- On Dec 21, 2021, H.C. Wainwright raises its price target to $69 from $62, keeps Buy.
- How does H.C. Wainwright's CYTK target compare with other analysts?
- Across 5 firms with a CYTK price target in the last 12 months, the median target is $95.
More CYTK rating histories
All H.C. Wainwright ratingsCYTK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.